pafuramidine maleate
Small moleculeexperimental
Pafuramidine is an experimental drug for the treatment of pneumocystis pneumonia (PCP). In 2006, pafuramidine was given orphan drug status by the US Food and Drug Administration for PCP in patients with HIV/AIDS. Preliminary clinical trials indicated that pafuramide was effective against pneumocystis pneumonia and had the potential for fewer side effects than the standard treatment with trimethoprim/sulfamethoxazole (TMP-SMX). — Wikipedia
Clinical trial activity
5 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2001 (NCT00802594)
Timeline
Indications
Mechanism of action
- Kinetoplast DNAINHIBITOR
Kinetoplast DNA inhibitor
Binds to the DNA minor groove in AT sequences of at least four consecutive AT base pairs
Chemistry & pharmacology
Loading structure…
SMILES
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1- Mol. weight
- 364.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL319669 ↗
- WikipediaPafuramidine ↗
- ChEMBLCHEMBL2107359 ↗
Also known as
- 2,5-bis(4-amidinophenyl)furan-bis-o-methylamidoxime
- db289
- db289
- db289
- db 289
- db-289
- db289 cpd
- pafuramidine
- pafuramidine
- pafuramidine
- pafuramidine maleate
- pafuramidine maleate
- pafuramidine maleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00619346 | Phase 1 | Nov 1, 2007 | Immtech Pharmaceuticals, Inc, Parexel |
| NCT00408369 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2006 | Immtech Pharmaceuticals, Inc, Johns Hopkins University |
| NCT00302341 | Phase 3 | May 1, 2006 | Henry Ford Health System, Immtech Pharmaceuticals, Inc, Medical University of South Carolina, New York University, University of California, San Francisco, University of Chicago, University of Cincinnati, University of North Carolina at Chapel Hill |
| NCT00803933 | Phase 2 | Feb 1, 2003 | Bill and Melinda Gates Foundation, Immtech Pharmaceuticals, Inc, Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine |
| NCT00802594 | Phase 2 | Aug 1, 2001 | Bill and Melinda Gates Foundation, Immtech Pharmaceuticals, Inc, University of Basel |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immtech Pharmaceuticals, Inc | For profit | 5 | 5 | 3 | 2001 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 0 | 1 | 2001 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2006 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Parexel | For profit | 1 | 0 | 1 | 2007 |
| Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Basel | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2006 |
13 organizations
Page 1 / 1